Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole
NCT ID: NCT02998437
Last Updated: 2017-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
28 participants
INTERVENTIONAL
2016-12-31
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects
NCT01921647
Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers
NCT05194046
To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration
NCT03011996
Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection
NCT02401477
Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori
NCT02873065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ilaprazole 10mg
Period 1: Ilaprazole 10mg 1 tab.m one a day
Period 2: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap. twice a day, 6 days Ilaprazole 10mg, one a day at the 5 day
Ilaprazole 10mg
Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
Clarithromycin 500mg
Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day
Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at the 5 day
Clarithromycin 500mg
Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
Amoxicillin 500mg
Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day
Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at 5 day
Amoxicillin 500 Mg
Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ilaprazole 10mg
Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
Clarithromycin 500mg
Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
Amoxicillin 500 Mg
Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body mass index ≥18.5 and \<25
* Body mass index (kg/m2) = body weight (kg)/\[height (m)\]2
3. Men who have sexual relationship with women of child bearing potential must give consent to using contraceptive measures (condoms, spermicide, and menstrual cycle control) and avoiding sperm donation during the study and up to 28 days following the last dose of IMP (these contraceptive measures are not required if the male subject or female partner is infertile).
4. Those who voluntarily decided to participate in this study and gave written consent to comply with the requirements after receiving sufficient explanation and fully understanding this study.
Exclusion Criteria
2. History of QT prolongation or ventricular arrhythmia (including Torsadedes de pointes)
3. Clinically significant, current or past disorder of hepatobiliary (severe hepatic impairment, etc.), renal (severe renal impairment, etc.), nervous, immune, respiratory, endocrine, blood•tumor, cardiovascular (heart failure, etc.), or psychiatric system
4. History of gastrointestinal disorder (Crohn's disease, ulcer, etc.) or operation (excluding simple appendectomy or herniotomy) that may affect drug absorption
5. Administration of other IMP from other study (including biological comparability test) within 3 months of the first dose of IMP.
6. Whole blood donation within 60 days, or apheresis donation within 30 days before the first dose of IMP.
7. Constant caffeine intake (\> 5 cups of coffee/day, \> 1250 cc of tea/day, \> 1250 cc of cola/day), constant smoking (more than 10 cigarettes/day) or constant alcohol drinking (more than 210 g/week) or inability to refrain from alcohol consumption from 2 days before the first dose of IMP until the end of PK assessment.
8. Consumption of grapefruit-containing food within 7 days before the first dose of IMP
9. History of drug abuse within 1 year before screening, or positive response in urine drug misuse/abuse screening test
10. Use of medicinal products that are expected to or may affect the metabolism of IMP; St. John's wort; or relevant preparations within 30 days of IMP administration
11. Use of following medicinal products within given time period excluding local preparations, which do not have significant systemic absorption, and hormonal contraceptives
* Prescription drug within 14 days of the first dose of IMP
* OTC including health supplements and vitamins within 7 days of the first dose of IMP
* Medicinal products via depot injection or other implantations within 30 days of the first dose of IMP (excluding contraceptives)
* Drug metabolizing enzyme inducer or inhibitor such as barbiturate within 30 days before the first dose of IMP
12. Stable vital sign measured in sitting position at screening: systolic blood pressure \> 150 mmHg or \< 90 mmHg, diastolic blood pressure \> 100 mmHg or \< 50 mmHg, pulse rate \> 110 bpm or \<40 bpm
13. Following findings at screening
* Blood total bilirubin \> 1.5 x upper limit of normal
* Blood AST (SGOT), ALT (SGPT) \> 1.25 x upper limit of normal
* MDRD-estimated eGFR \< 60 mL/min/1.73m2 eGFR (estimated glomerular filtration rate)(mL/min/1.73m2) = 175 x \[serum creatinine (mg/dL)\]-1.154 x \[age (years)\]-0.203
* Positive serum test (hepatitis B, hepatitis C, HIV, syphilis)
14. Those considered ineligible by the investigator due to other screening results or reasons.
19 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Severance Hospital
OTHER
Il-Yang Pharm. Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Min MS Park, PhD
Role: PRINCIPAL_INVESTIGATOR
Severance Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jin BH, Yoo BW, Park J, Kim JH, Lee JY, Shin JS, Park MS. Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study. Eur J Clin Pharmacol. 2018 Sep;74(9):1149-1157. doi: 10.1007/s00228-018-2489-2. Epub 2018 May 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IY81149-DI03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.